



Supplementary Figure S1: (A) Western blot analysis of whole cell lysate from adherent and PCS. Representative blots show enhanced SNA and MALII binding in PCS. β -actin used as a loading control. (B) Representative immunoblots exhibited higher expression of Neu2 upon overexpression in PCS from both MIAPaCa2 and AsPC1 cells. β -actin used as a loading control. (C) Western blot analysis demonstrated reduced expression of pluripotent stem cell markers Oct4, Sox2 and Nanog in Neu2-overexpressed PCS. β -actin used as a loading control. (D) Western blot analysis of whole-cell lysate from PCS and N-PCS. Representative blots show decreased SNA and MALII binding in

N-PCS. β -actin used as a loading control. **(E)** qPCR analysis shows higher expression of pro-apoptotic genes such as CAS 3, 7, 8 and BAX and reduced expression of anti-apoptotic BCL2 in Neu2-overexpressed PCS from both MIAPaCa2 and AsPC1 cells.

S2



Supplementary Figure S2: (A) qPCR data represent an enhanced expression of Hedgehog pathway genes such as PTCH1, GLI1, GLI2, GLI3, SMO, SHH and SUFU in pancreatic cancer sphere-forming cells generated from both MIAPaCa2 and AsPC1 cells. (B) qPCR analysis showed reduced expression of Hedgehog pathway genes such as PTCH1, GLI1, GLI2, GLI3, SHH, SUFU and SMO in Neu2-overexpressed PCS generated from both MIAPaCa2 and AsPC1 cells.



Supplementary Figure S3.: (A) Representative immunoblots exhibited enhanced mTORC1/2 formation and higher expression of Rictor and Raptor in PCS from both cell lines. β -actin used as a loading control. (B) Western blots analysis show inhibition of Gsk3 β and activation of Akt in PCS from both cell lines. β -actin used as a loading control. (C) Representative immunoblots exhibited enhanced mTORC2 formation and Rictor expression at protein levels in Rictor-overexpressed PCS whereas reduced expression of these molecules was found in Rictor and Neu2 co-overexpressed PCS.

Supplementary Table 1: List of Primers.

NAME	FORWARD PRIMER (5'-3')	REVERSE PRIMER (5'-3')
OCT 4	GAGGAGTCCCAGGACATCAA	ACACTCGGACCACATCCTTC
SOX 2	AGAACCCCAAGATGCACAAC	ATGTAGGTCTGCGAGCTGGT
NANOG	ACCAGACCCAGAACATCCAG	CTCGTTCGATTAGGCTCCAAC
CD133	TTGTGGCAAATCACCAGGTA	TCAGATCTGTGAACGCCTTG
GLI1	GTGCAAGTCAAGCCAGAACA	ATAGGGGCCTGACTGGAGAT
GLI2	TTTATGGGCATCCTCTCTGG	AAGGCTGGAAAGCACTGTGT
GLI 3	TCCCAGCGCTTTCTACATCT	CTTTGTTCGTGGACCCATTCT
PTCH1	TCCCAGCGCTTTCTACATCT	CTTTGTTCGTGGACCCATTCT
SHH	TACTCGCAGCTGCTCTACCA	TGTCCTTTTTGCTTTGCGTTG
SMO	CAACCTGTTTGCCATGTTTG	TTTGGCTCATCGTCACTCTG
Neu1	GGAGCAAGGATGATGGTGTT	CATGATCATCGCTGAGGAGA
Neu2	CCTCTTCTTCATTGCCATCC	GTCGTGAAGCTGCAAACAAT
Neu3	CAGATTGTGTCAGGCAGGAA	AGCTGGAAGCAAAGAACCA
Neu4	CACCGTCTTCCTCTTCTTCA	GGCAGATCTTGCCAAAACA
Caspase 8	AGACTGATTCAGAGGAGCAA	GTGACTGGATGTACCAGGTT
Caspase 7	GATTTGACAGCCCACTTTAG	TTCCACTGGGATCTTGTATC
Caspase 3	AGGAGCAGTTTTGTTTGTGT	CAGGCCTGAATAATGAAAAG
Bax	TCACTGAAGCGACTGATGT	GAGGAAAAACACAGTCCAAG
Bcl2	ATTGTGGCCTTCTTTGAGT	TACAGTTCCACAAAGGCATC
18s rRNA	GCTCATTAAATCAGTTATGG	ACTACCATCGAAAGTTGATA